16th Biosimilars Congregation 2021

16th Biosimilars Congregation 2021 is organized by Virtue Insight and will be held on Dec 09, 2021.

Who Should Attend and Who You’ll Meet:
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
Biopharmaceuticals/Biotherapeutics, Follow on Biologics/Follow on Proteins, Biologics/Biotechnology/ Bio generics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affair

Description:
The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keep adding to the hindrance in their development.

2030, India will become the sixth-largest market for pharmaceuticals, and it has firmly established itself in the global biopharmaceutical market. Many of the Indian pharmaceutical companies are preparing to step into the global biosimilars market. As per the report of 2017, biosimilars represent a 30% compound annual growth rate. They are worth $2.2bn out of the $32bn total Indian pharma market and are estimated to reach $40bn by the year 2030.

At 16th Biosimilars Congregation 2021 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community

Why to attend???
Join your peers around the world focused on learning about Biologics and Biosimilars related advances, which is your single best opportunity to reach the largest assemblage of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with new research works, and receive name recognition at this 1-day event. Well-renowned speakers, the most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

Key Speakers:
• ARANI CHATTERJEE, Senior Vice President, Clinical Research, Aurobindo
• PHILIP SCHNEIDER, Chair, International Advisory Board, Alliance for Safe Biologic Medicines(USA)
• MICHEL MIKHAIL, International Expert in Regulatory Affairs, Global Expert in Biosimilars (Germany)
• RAHUL GUPTA, Vice President, Regulatory Affairs, USV
• MARTA BALDRIGHI, Policy and Science Officer, Medicines for Europe (Belgium)
• SHALIGRAM RANE, Vice President of Quality, Lupin
• NARENDRA MAHARAJ, Vice President and Head, Clinical Development and Biologics, Dr. Reddy's Laboratories
• DIVYA BIJLWAN, Senior Vice President, Business Development, Aurobindo
• PRAVEEN KUMAR L, Director - Regulatory Affairs, Cipla
• PIRTHI PAL SINGH, Associate Vice President, Head R&D - Differentiated Formulations, Dr. Reddy's Laboratories
• PAWAN SINGH, Senior Medical Director, Biocon
• KUMAR GAURAV, Director Medical Affairs, Dr. Reddy's Laboratories
• MILIND ANTANI, Leader, Pharma and Healthcare, Nishith Desai Associates
• ARUN BHATT, Consultant – Clinical Research & Development
• NITISH CHAKRAVARTY, Vice President - Secondary Manufacturing, Biological E. Limited
• KANTHIKIRAN VARANASI, Vice President and Head - Clinical Research & Operations, Galenicum
• GAURAV SAHAL, Head of Global Patent Prosecution, Sun Pharma
• ADITYA SHARMA, Head - BioProcessing Business, Merck Life Science
• NIBEDITA RATH, Scientific Director, Open Source Pharma Foundation 
• UDIT SAKHUJA, Head Of Marketing, Dr. Reddy's Laboratories
• SONAL SHAH, Head Marketing – Biosimilars, Cadila
• SWEETY MATHEW, Global Regulatory Affairs, Biocon
• RAHUL CHAUHAN, Head- Regulatory Affairs, Takeda
• ALOK SHARMA, Head & GM, Quality Control, Lupin
• TUSHAR NAIK, Consultant & Advisor, GLG(USA) (Former Senior GM, Zydus Group)
• RAVI SHANKARA, Senior General Manager (R & D) & Functional Head -Analytical Development - Biologics and Peptides, Sun Pharma
• MAHENDRA SHIRADKAR, Lead: FDS Project and Portfolio Management, Viatris
• PRAVIN A. NAIR, Head Drug Product Development (R&D), Intas Pharmaceuticals (Biopharma Division)
• KAVYA KADAM, Consultant, Global Clinical Trials
• HARSHAD KOTHAWADE, Head-Regulatory Management & Trade Compliance, Merck

Key Themes Discussed:
• Recent trends and new normal in Biosimilars - How to excel with this?
• Development challenges on the biosimilars products for companies? What are the remedies?
• Pharmacovigilance and risk management of biosimilars.
• Successful business models and dealing with every ambiguity mAbs - Could be a game changer in India
• Impact of the pandemic - affecting the biosimilar markets
• Ways for smart handling of market access, sustainable pricing and reimbursement of biosimilars in the market.
• Challenges and changes interchangeability
• How does strategic planning really help to grow market opportunities?
• Market barriers for biosimilar approval in India market.
• Future opportunities for product development
• Risk of adverse effects related to new drug development. How to overcome that?
• Newer versions of generic drugs truly increase the value of the market?
• How to speed up the process of development and reduce costs of production?
• Regulators view on interchangeability and switching biosimilars.
• How to minimise the rejection of biosimilar applications while evaluating regulatory bodies?
• Next 5 years in the field of biosimilars regulations

Why Should You Attend?
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

What are the benefits of attending?
• Meet your peers in an interactive, discussion-based format designed to maximize knowledge transfer and networking
• Enjoy our informal networking at drinks and lunch
• Meet the leading solution providers in the market to forge partnerships and discover solutions
• Receive electronic versions of the conference documentation for use of reference post-event.
• Get ideas for?training topics?that you might want to present as professional development sessions to others in your workplace.
• Observe speakers from the perspective of seeing what works really well so you can learn new public speaking techniques and strategies that you can apply when doing your own presentations.
• Learn what not to do in presentations if you end up sitting through any sessions that fail to be engaging or informative.
• Delegates also benefit from discounted rates onfuture event attendance